Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells

Annals of Nuclear Medicine

Volumn 15, Issue 6, 2001, Pages 499-504

  Obata, Atsushi ^a,b   Yoshimi, Eiji ^b   Waki, Atsuo ^a,c   Lewis, Jason S ^c   Oyama, Nobuyuki ^c   Welch, Michael J ^c   Saji, Hideo ^b   Yonekura, Yoshiharu ^a   Fujibayashi, Yasuhisa ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Bioreductive enzyme; Cu ATSM; Hypoxia; Microsome

Indexed keywords

COPPER 64; COPPER DIACETYLBIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; CYTOCHROME B5 REDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN MICROSOME; BRAIN MITOCHONDRION; CELL FRACTIONATION; CONTROLLED STUDY; CYTOSOL; EHRLICH ASCITES TUMOR CELL; HYPOXIA; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; BRAIN; CARCINOMA, EHRLICH TUMOR; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; MICE; MICE, INBRED STRAINS; MODELS, CHEMICAL; NAD; NADP; ORGANOMETALLIC COMPOUNDS; OXIDATION-REDUCTION; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES;

EID: 0035708693     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02988502     Document Type: Article

References (34)

1. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential
2. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: Ex vivo imaging of hypoxia in rats
3. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model
4. 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer
5. Evaluation of copper-60 diacetylbis(N4-methylthiosemicarbazone) (Cu-ATSM), a hypoxia imaging agent in canine models of ischemia
6. Copper-62-ATSM as a hypoxic tissue tracer in myocardial ischemia
7. Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy
8. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia
9. 67Cu
10. 4-methylthiosemicarbazone): An agent for radiotherapy
11. 62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging
12. 4-methylthiosemicarbazone) (Cu-PTSM)
13. The preparation of some thiosemicarbazones and their copper complexes
14. 4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: A novel radiopharmaceutical for positron emission tomography imaging
15. Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells
16. The respiratory chain and the oxidative phosphorylation of rat brain mitochondria
17. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia
18. Cellular approaches to bioreductive drug mechanisms
19. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
20. Non-enzymatic and enzymatic activation of mitomycin C: Identification of a unique cytosolic activity
21. DT diaphorase
22. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin
23. Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase
24. Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs
25. Soluble NADH-cytochrome b5 reductase from rabbit liver cytosol: Partial purification and characterization
26. + reductase: Prototype for a structurally novel flavoenzyme family
27. Propylthiouracil, a selective inhibitor of NADH-cytochrome b5 reductase
28. Comparative analysis of the cytotoxicity of substituted (phenylglyoxal bis(4-methyl-3-thiosemicarbazone)) copper(II) chelates
29. Initial reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II) with Ehrlich ascites tumor cells
30. 4methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: A potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography (PET)
31. Bioreductive drugs into the next millennium
32. Targeting hypoxia with a new generation of indolequinones
33. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)